Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
7.91
+0.27 (3.53%)
At close: May 29, 2026, 4:00 PM EDT
7.94
+0.03 (0.38%)
After-hours: May 29, 2026, 7:10 PM EDT

Company Description

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.

Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings logo
CountryUnited States
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees36
CEOYuval Cohen

Contact Details

Address:
500 River Ridge Drive
Norwood, Massachusetts 02062
United States
Phone617 963 0100
Websitecorbuspharma.com

Stock Details

Ticker SymbolCRBP
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595097
CUSIP Number21833P103
ISIN NumberUS21833P3010
Employer ID46-4348039
SIC Code2834

Key Executives

NamePosition
Dr. Yuval Cohen Ph.D.Chief Executive Officer and Director
Sean F. Moran CPA, M.B.A.Chief Financial Officer

Latest SEC Filings

DateTypeTitle
May 29, 2026S-8Securities to be offered to employees in employee benefit plans
May 26, 20268-KCurrent Report
May 21, 20268-KCurrent Report
May 14, 2026SCHEDULE 13G/AFiling
May 14, 20268-KCurrent Report
May 12, 202610-QQuarterly Report
May 12, 20268-KCurrent Report
Apr 16, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 16, 20268-KCurrent Report
Apr 14, 20268-KCurrent Report